10x Genomics (TXG) Change in Cash (2018 - 2026)

10x Genomics (TXG) has 9 years of Change in Cash data on file, last reported at $16.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 50.54% year-over-year to $16.3 million; the trailing twelve-month figure through Mar 2026 stood at $113.2 million (up 432.07% YoY), and the FY2025 full-year result was $129.9 million, up 953.64% from the prior year.
• Change in Cash retreated to $16.3 million in Q1 2026, from $41.3 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $112.4 million in Q1 2023 to a low of -$276.0 million in Q1 2022.
• A 5-year average of -$6.2 million and a median of $16.3 million in 2026 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash plunged 906.61% in 2022 and soared 1041.88% in 2025, its largest moves.
• Tracing TXG's Change in Cash over 5 years: stood at -$14.2 million in 2022, then soared by 413.77% to $44.5 million in 2023, then tumbled by 221.43% to -$54.1 million in 2024, then surged by 176.27% to $41.3 million in 2025, then plunged by 60.45% to $16.3 million in 2026.
• Business Quant data shows TXG's Change in Cash at $16.3 million in Q1 2026, $41.3 million in Q4 2025, and $35.0 million in Q3 2025.